EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group

Oana O Bulaicon iD, Femke M van Haalen iD, Gavin P R Clunie iD, Corinna Grasemann iD, Willem F Lems iD, Polyzois Makras iD, Geert Mortier iD, Ralf Oheim iD, Adalbert Raimann iD, Heide Siggelkow iD, Gaia Tabacco iD, Robert J P van der Wal iD und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 17.06.2026 · 111 (7) · e1760-e1773

DOI: 10.1210/clinem/dgag154 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.04.2026. Verfasst von Oana O Bulaicon und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Bone Quality, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Bone Diseases, Rare Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Rare bone diseases (RBDs) may display a disrupted RANKL-RANK-osteoprotegerin pathway causing increased osteoclastogenesis and enhanced bone resorption. Although bisphosphonates are commonly used, they often fall short of desired outcomes. Denosumab, an anti-RANKL antibody, provides a promising alternative by swiftly and strongly suppressing bone turnover (faster and more potent suppression of bone resorption than bisphosphonates), though its effects are reversible on discontinuation. The use of denosumab has been highlighted, especially in pediatric cases, but not substantially in adults. Evidence Acquisition A targeted evidence search was conducted to retrieve studies reporting denosumab use in RBDs in adults. Evidence Synthesis Denosumab administration may lead to pain reduction, lesion reduction, or bone formation. Treatment dosage, schedules, and duration varied, however, a dose of 120 mg dosed monthly or every 3 months for almost 1 year reached the desired treatment effect in most patients. Denosumab is generally well tolerated in adults, with mild common side effects such as (asymptomatic) hypocalcemia and hypophosphatemia. Serious adverse effects such as osteonecrosis of the jaw or atypical femoral fractures are rarely reported. Main concerns regard rebound effect after denosumab discontinuation, with disease recurrence in some cases. Zoledronic acid after discontinuation of denosumab might be advisable, but is seldom reported.

Conclusion

Denosumab is a feasible treatment in adults with RBDs when managed by multidisciplinary teams with knowledge of both the underlying disease and potential surgeries as well as the medical site of treatment. Denosumab discontinuation management is paramount to prevent recurrence and severe complications. The paucity of data supports the need for data collection through rare disease registries for future pertinent evidence-based recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBone Density Conservation AgentsBone DiseasesRare DiseasesHumansAdultRANK Ligand

Stichwörter der Autor:innen

McCune-Albright syndromeRANKLaneurysmal bone cystcherubismdenosumabfibrous dysplasiarare bone diseases

Substanzen

DenosumabBone Density Conservation AgentsRANK Ligand

Autor:innen und Institutionen

  • Center for Bone Quality, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
  • Metabolic Bone Physician, Cambridge University Hospitals, Box 204, Hills Rd, Cambridge CB2 0QQ, UK.
  • Department of Pediatrics, Katholisches Klinikum Bochum, Ruhr-University Bochum, Bochum 44791, Germany.
  • Department of Rheumatology, Amsterdam University Medical Center, 1105 AZ Amsterdam, the Netherlands.
  • LCH Adult Clinic, Department of Medical Research, and Department of Endocrinology and Diabetes, 251 Hellenic Air Force and VA General Hospital, Athens 11525, Greece.
  • Center for Human Genetics, University Hospital Leuven and KU Leuven, Leuven B-3000, Belgium.

ORCID-Profile: Oana O Bulaicon, Femke M van Haalen, Gavin P R Clunie, Corinna Grasemann, Willem F Lems, Polyzois Makras, Geert Mortier, Ralf Oheim, Adalbert Raimann, Heide Siggelkow, Gaia Tabacco, Robert J P van der Wal, Pieter B de Witte, Natasha M Appelman-Dijkstra

Zitieren

APA

Bulaicon, O. O., van Haalen, F. M., Clunie, G. P. R., Grasemann, C., Lems, W. F., Makras, P., Mortier, G., Oheim, R., Raimann, A., Siggelkow, H., Tabacco, G., van der Wal, R. J. P., de Witte, P. B., & Appelman-Dijkstra, N. M. (2026). The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group. The Journal of Clinical Endocrinology & Metabolism, 111(7), e1760-e1773. https://doi.org/10.1210/clinem/dgag154

Vancouver

Bulaicon OO, van Haalen FM, Clunie GPR, Grasemann C, Lems WF, Makras P, et al. The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group. The Journal of Clinical Endocrinology & Metabolism. 2026;111(7):e1760-e1773. doi:10.1210/clinem/dgag154

BibTeX
@article{Bulaicon2026,
  author = {Bulaicon, Oana O and van Haalen, Femke M and Clunie, Gavin P R and Grasemann, Corinna and Lems, Willem F and Makras, Polyzois and Mortier, Geert and Oheim, Ralf and Raimann, Adalbert and Siggelkow, Heide and Tabacco, Gaia and van der Wal, Robert J P and de Witte, Pieter B and Appelman-Dijkstra, Natasha M},
  title = {The use of denosumab in rare bone diseases in adults: a systematic review from the ECTS Rare Bone Disease Action Group},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {7},
  pages = {e1760--e1773},
  doi = {10.1210/clinem/dgag154}
}
Kostenlos starten →